ASH 2022

Bispecific antibodies - consolidating data, clinical implications & combinational aspects

Treatment of high-risk NDMM patients and MRD-driven deescalation perspectives

Asymptomatic myeloma - what do we really want to achieve?

CAR-T cells - manufacturing, earlier lines & new targets

Glofi - RCHOP in 1st line, Axi-Cel in 2nd line, TMTV post Axi-Cel, Non-Relapse mortality after CART

Zanu with superior PFS, Pirtobrutinib Update in R/R CLL/SLL, MRD Stopping in CLL

Do we treat all MCL identically? New data on Ibru, Tisagenlecleucel and ALR …

When to treat or not? Watch and wait!? Bispecifics or CART? Do we need a new FLIPI-Score?

NDMM highlights

Establish MRI diagnostics early

To transplant or not?

Maintenance with lenalidomide - how long?

Quadruplet for newly diagnosed high-risk patients

NDMM highlights

MRD-Diagnostik früh etablieren

Isa-KRd bei HR NDMM: Hohe MRD Negativität

Erhaltung mit Lenalidomid - wie lange?

Kortikoid-Einsparung bei unfitten Patienten unter DR

Bispecific antibodies highlights

More treatment options with bispecifics emerging!

New CAR-T technologies

The future of immunotherapy

CAR-T cells: new targets and early treatment

New generation CAR-T cell therapy with fast availability

Bispecific antibodies

GPRC5D-immunotherapy

Still biting, Talquetamab?

Bispecific antibodies highlights

Neue Generation der CAR-T Zelltherapie mit schneller Verfügbarkeit

Die Zukunft der Immuntherapie

Bispezifische Antikörper: Weitere Behandlungsoptionen in Sicht

Bispesifikke antistoffer

CAR-T Zellen: Neue erfolgsversprechende Targets und frühere Anwendung

Nye CAR-T-teknologier

GPRC5D immunterapi

Smouldering myeloma - potentially curable?

Plasma cells aren't alone!

Smouldering Myelom – potentiell heilbar?

Ibrutinib combined with chemotherapy could replace ASCT

Glofitamab in R/R mantle cell lymphoma

Early use of anti-CD19 CAR-T (tisacel) plus ibrutinib is highly effective in r/r MCL, including cases with high risk features and/or previous use of BTKi

The R2-Acalabrutinib combination in first-line is highly effective and manageable in MCL, allowing for a time-limited treatment in those cases achieving deeper responses

VALERIA response-adapted treatment for R/R MCL patients

TRIANGLE - addition of Ibrutinib will improve outcome for younger MCL patients

Glofitamab demonstrates high efficacy in r/r MCL

Ibrutinib + Ctx replaces autologous stem cell transplantation

Ibrutinib added in induction and maintenance improves efficacy and FFS after the first line in younger patients with MCL and challenges the role of autologous transplant consolidation

Fixed-duration Glofitamab produces high quality and durable responses with a favourable toxicity profile in patients with r/r MCL

Ibrutinib + Ctx ersetzt autologe Stammzelltransplantation

Valeria- responsstyrd behandling för recidiverande MCL

El triplete R2-Acalabrutinib en primera línea es altamente eficaz y manejable en el LCM, permitiendo limitar la duración del tratamiento en los casos con respuestas más profunda

Glofitamab en esquema fijo de 12 meses produce respuestas duraderas y de alta calidad en pacientes con LCM en recaída/refractario, con un favorable perfil de seguridad

Glofitamab för recidiverande MCL

Ibrutinib en inducción y mantenimiento mejora la eficacia y la supervivencia tras la primera línea en pacientes jóvenes con LCM, cuestionando el papel de la consolidación con transplante autólogo

TRIANGLE- tillägg av ibrutinib förbättrar behandlingsutfall för yngre patienter med MCL

El uso precoz de CAR-T anti-CD19 (tisacel) e ibrutinib es muy eficaz en el LCM en recaída, incluyendo casos de alto riesgo biológico y/o previo uso de iBTK

Is watch & wait still valualble in follicular lymphoma?

Bispecific antibody Epcoritamab s.c. + R2 convincing

A new FLIPI to predict POD24 in follicular lymphoma

Watch and Wait remains standard of care

Epcoritamab - bispecific antibody highly effective in r/r FL

Odronextamab in relapsed/refractory follicular lymphoma

Tisagenlecleucel at r/r FL: convincing response more than 2 years

Epcoritamab-R2 nel linfoma follicolare recidivato/refrattario

Tisagenlecleucel beim r/r FL: Überzeugendes Ansprechen mehr als 2 Jahre

Bispezifischer Antikörper Epcoritamab s.c. + R2 überzeugend

E' ancora valido il watch & wait nel linfoma follicolare?

Watch and Wait bleibt Standard

Odronextamab nel linfoma follicolare recidivato/refrattario

Un nuovo FLIPI per predire la POD24 nel linfoma follicolare

Two highlight studies in DLBCL treatment

Alycante - axi-cel in transplant-ineligible R/R DLBCL patients

Deux études marquantes dans le traitement du DLBCL

Alycante - axi-cel till patienter med tidigt recidiv av DLBCL, som inte är aktuella för ASCT

Ventricular arrhythmias under combination ibrutinib + venetoclax

Ventrikuläre Arrhythmien unter Kombi Ibrutinib + Venetoclax

Pirtobrutinib shows activity in pre-treated r/r patients

Zanubrutinib demonstrates superiority in r/r CLL/SLL

Is it time to feed our patients?